# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Goldman Sachs analyst Tommie Reerink maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Sell and lowers the price target f...
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025If Approved, Tab-cel Would Be First Approved Thera...
ATA3219 Demonstrates Complete CD19-Specific B-Cell Depletion Against Systemic Lupus Erythematosus and Multiple Sclerosis Patien...
HC Wainwright & Co. analyst Robert Burns reiterates Atara Biotherapeutics (NASDAQ:ATRA) with a Neutral.